Pre- and postoperative radiotherapy for extremity soft tissue sarcoma: Evaluation of inter-observer target volume contouring variability among French sarcoma group radiation oncologists

Sargos, P.; Charleux, T.; Haas, Rick L.; Michot, Audrey; Llacer, C.; Moureau-Zabotto, L.; Vogin, Guillaume; Péchoux, C. Le; Verry, Camille; Ducassou, A.; Delannes, M.; Mervoyer, A.; Wiazzane, N.; Thariat, Juliette; Sunyach, Marie‐Pierre; Benchalal, M.; Laredo, Jean‐Denis; Kind, Michèle; Gillon, P.; Kantor, G.

doi:10.1016/j.canrad.2017.09.004

Cited by 7 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, lack of sufficient contrast resolution and functional information can lead to inadequate information on the tumor spatial extents. This limitation leads to large variability in defining the extent of disease, regardless of the specific disease site . To address those limitations, other imaging exams are frequently incorporated to complement CT images.…”

Section: Introductionmentioning

confidence: 99%

“…This limitation leads to large variability in defining the extent of disease, regardless of the specific disease site. [1][2][3][4][5][6][7][8][9] To address those limitations, other imaging exams are frequently incorporated to complement CT images. One such imaging system is Positron emission tomography (PET), which utilizes radioactive tracers to provide an image of tissue biological activity.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Task Group 174 Report: Utilization of [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography ([¹⁸F]FDG‐PET) in Radiation Therapy

et al. 2019

View full text Add to dashboard Cite

The use of positron emission tomography (PET) in radiation therapy (RT) is rapidly increasing in the areas of staging, segmentation, treatment planning, and response assessment. The most common radiotracer is 18F‐fluorodeoxyglucose ([18F]FDG), a glucose analog with demonstrated efficacy in cancer diagnosis and staging. However, diagnosis and RT planning are different endeavors with unique requirements, and very little literature is available for guiding physicists and clinicians in the utilization of [18F]FDG‐PET in RT. The two goals of this report are to educate and provide recommendations. The report provides background and education on current PET imaging systems, PET tracers, intensity quantification, and current utilization in RT (staging, segmentation, image registration, treatment planning, and therapy response assessment). Recommendations are provided on acceptance testing, annual and monthly quality assurance, scanning protocols to ensure consistency between interpatient scans and intrapatient longitudinal scans, reporting of patient and scan parameters in literature, requirements for incorporation of [18F]FDG‐PET in treatment planning systems, and image registration. The recommendations provided here are minimum requirements and are not meant to cover all aspects of the use of [18F]FDG‐PET for RT.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Task Group 174 Report: Utilization of [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography ([¹⁸F]FDG‐PET) in Radiation Therapy

et al. 2019

View full text Add to dashboard Cite

show abstract

“… 22 Sargos et al, distributed co-registered CT and MRI images to six radiation oncologists, demonstrating substantial agreement by κ statistics in a single pre-operative patient. 24 However, the above studies did not directly compare inter- and intraobserver variation between CT and MRI.…”

Section: Discussionmentioning

confidence: 98%

Does magnetic resonance imaging improve soft tissue sarcoma contouring for radiotherapy?

et al. 2019

View full text Add to dashboard Cite

Objective: Soft tissue sarcomas (STS) are a rare, heterogeneous tumour group. Radiotherapy improves local control. CT is used to plan radiotherapy, but has poor soft tissue definition. MRI has superior soft tissue definition. Contour variation amongst oncologists is an important factor in treatment failure. This study is the first to directly compare STS tumour contouring using CT vs MRI. Methods: Planning CT and T2 weighted MR images of eight patients with STS were distributed to four oncologists. Gross tumour volume was contoured on both imaging modalities using in-house software. Images were recontoured 6 weeks later. The mean distance to agreement (DTA), standard deviation of the DTA, dice similarity coefficient (DSC) and contour volume were calculated for each oncologist and compared to a median contour volume. Results for CT and MRI were compared using a pairwise Student's t-test. Results: When comparing MRI to CT, tumour volumes were significantly smaller, with a difference of 21.4 cm3 across all patients (p = 0.008). There was not a statistically significant difference in the mean distance to agreement or dice similarity coefficient, but the standard deviation of the DTA showed a statistically significant improvement ( p = 0.04). For intraobserver variation, there was no statistically significant improvement using MRI vs CT. Conclusion: Oncologists contour smaller tumour volumes using MRI, with reduced interobserver variation. Improving the reliability and consistency of contouring is needed for improved quality assurance. Advances in knowledge: With further experience, the use of MRI in STS radiotherapy planning may reduce variation between oncologists and contribute to improved local control and reduced treatment toxicities.

show abstract

“…Clinical Trials.gov identifier (NCT number): NCT02106312. Radiotherapy target for myxoid liposarcoma is the same as radiation target in pre-operative radiotherapy in other soft tissue sarcoma: 40,41 1. Gross Tumor Volume (GTV) based on the preoperative sequence of T1 in MRI with gadolinium contrast.…”

Section: Radiotherapymentioning

confidence: 99%

Preoperative Radiotherapy in Myxoid Liposarcoma

Tjuatja

Djakaria

2021

Radioter Onkol Indones

View full text Add to dashboard Cite

Myxoid liposarcomas are responsive to radiotherapy, particularly preoperative radiotherapy. The expected outcome of the preoperative radiation is a decreasing tumor size and major necrotizing area. With a good local control, organs can survive without any amputation. Preoperative radiotherapy can be given with or without chemotherapy. Conventional fractionation such as 25 x 2 Gy or hypofractionation of 5 x 5 Gy could be an effective way to treat preoperative myxoid liposarcoma.

show abstract

Pre- and postoperative radiotherapy for extremity soft tissue sarcoma: Evaluation of inter-observer target volume contouring variability among French sarcoma group radiation oncologists

Cited by 7 publications

References 30 publications

Task Group 174 Report: Utilization of [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography ([¹⁸F]FDG‐PET) in Radiation Therapy

Task Group 174 Report: Utilization of [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography ([¹⁸F]FDG‐PET) in Radiation Therapy

Does magnetic resonance imaging improve soft tissue sarcoma contouring for radiotherapy?

Preoperative Radiotherapy in Myxoid Liposarcoma

Contact Info

Product

Resources

About

Pre- and postoperative radiotherapy for extremity soft tissue sarcoma: Evaluation of inter-observer target volume contouring variability among French sarcoma group radiation oncologists

Cited by 7 publications

References 30 publications

Task Group 174 Report: Utilization of [18F]Fluorodeoxyglucose Positron Emission Tomography ([18F]FDG‐PET) in Radiation Therapy

Task Group 174 Report: Utilization of [18F]Fluorodeoxyglucose Positron Emission Tomography ([18F]FDG‐PET) in Radiation Therapy

Does magnetic resonance imaging improve soft tissue sarcoma contouring for radiotherapy?

Preoperative Radiotherapy in Myxoid Liposarcoma

Contact Info

Product

Resources

About

Task Group 174 Report: Utilization of [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography ([¹⁸F]FDG‐PET) in Radiation Therapy

Task Group 174 Report: Utilization of [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography ([¹⁸F]FDG‐PET) in Radiation Therapy